Overview
Pexidartinib (PLX3397) is a small molecule inhibitor targeting colony-stimulating factor 1 receptor (CSF1R), KIT, and FLT3 tyrosine kinases. Developed as an oral therapeutic agent, it received FDA approval in 2019 for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adults where surgery is not recommended. The drug represents a breakthrough in targeted therapy for rare tumors, offering an alternative to surgical resection. Its development reflects the growing importance of precision medicine in oncology, particularly for conditions with limited treatment options.
Physical and Chemical Properties
Pexidartinib appears as a white to off-white solid with a molecular weight of 412.37 g/mol. The compound demonstrates good stability when stored properly at -20°C in a dry environment, protected from light. Chemically, it features a unique structure containing trifluoromethyl and pyrimidine groups, which contribute to its selective binding to target kinases. The drug shows solubility in dimethyl sulfoxide (DMSO) and limited solubility in ethanol, which is important for formulation development.
Main Applications
The primary clinical application of pexidartinib is in the treatment of tenosynovial giant cell tumor (TGCT), a rare non-malignant tumor that can cause severe morbidity. It is specifically indicated for cases where surgical resection would result in worsening functional limitations or severe morbidity. Beyond TGCT, pexidartinib has shown potential in clinical trials for other CSF1R-dependent conditions, including certain leukemias and solid tumors. Research continues to explore its efficacy in combination therapies and additional oncological indications.
Safety and Storage
Pexidartinib requires careful handling as it poses health hazards through various exposure routes. Laboratory personnel should use appropriate personal protective equipment, including gloves and eye protection, when working with the compound. For long-term storage, pexidartinib should be kept at -20°C in a tightly sealed container, protected from moisture and light. The drug's stability may be compromised by exposure to high temperatures or humidity, emphasizing the need for proper storage conditions throughout the supply chain.
B2B Procurement Guide
Pharmaceutical companies and research institutions sourcing pexidartinib should verify suppliers' Good Manufacturing Practice (GMP) certifications and regulatory compliance documentation. The compound is typically available in small quantities for research purposes and in larger batches for clinical applications. When evaluating suppliers, consider their track record in API production, quality control documentation, and ability to provide certificates of analysis. Given the specialized nature of this compound, procurement professionals should allow for longer lead times compared to more common pharmaceutical ingredients.
Related Manufacturers
- 主营：小分子现货、科研小分子、单抗、培西达替尼盐酸盐、多肽、RAS抑制剂、中间体、医药中间体、实验室用试剂、实验小分子、氯苯甲酸、咪唑乙醇、氧代丙腈、贝达喹啉、贝伐单抗、谷氨酰胺、喹啉-21氢、决明内酯、溴喹唑啉、苯基丙基、乙基己基